Markers of Glycemic Control and Neonatal Morbidity in High-Risk Insulin-Resistant Pregnancies

Abstract

Objective This study aims to determine whether fructosamine, glycated hemoglobin A_1C (HbA_1c), or mean fasting glucose levels associate with birth outcomes in diabetic women.

Study Design A prospective cohort study of women with singleton, nonanomalous pregnancies and diagnosis of diabetes (gestational or pregestational). Daily average self-measured fasting serum glucose levels were collected, as well as HbA_1c and fructosamine levels at delivery. The primary outcome was neonatal composite morbidity, defined as having one or more of the following: respiratory distress syndrome, hyperbilirubinemia, perinatal death, shoulder dystocia, and hypoglycemia requiring treatment. Secondary outcomes included macrosomia (≥ 4,000 g).

Results Among neonates delivered by 301 study-eligible women (97 with gestational and 204 with pregestational diabetes), incidences of composite morbidity (n = 147, 48.8%) and macrosomia (n = 49, 16.3%) were high. Macrosomia occurred more frequently in infants of pregestational than gestational diabetic mothers (22.7 vs. 13.2%, p = 0.04), composite morbidities were not significantly different (52.2 vs. 42.3%, p = 0.14). HbA_1c > 8.0 significantly increased risk of morbidity and macrosomia (relative risk, 4.29; 95% confidence interval, 1.62–11.3).

Conclusions Late third-trimester HbA_1c, but not fructosamine or mean blood glucose levels, was associated with increased morbidity in infants of diabetic mothers. Third-trimester HbA_1c could be clinically useful for counseling regarding neonatal risks in women with diabetes.

Keywords

pregnancy - insulin resistance - glucose - neonatal outcomes

Note

This work was supported by the Thrasher Foundation (A. G. C.). This study was presented as a poster at: 33rd Annual Meeting of the Society of Maternal–Fetal Medicine; February 11–16, 2013; San Francisco, CA.

• References

• 1 Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am 2007; 34 (2) 173-199 , vii
• 2 Mayorga ME, Reifsnider OS, Neyens DM, Gebregziabher MG, Hunt KJ. Simulated estimates of pre-pregnancy and gestational diabetes mellitus in the US: 1980 to 2008. PLoS ONE 2013; 8 (9) e73437
• 3 Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008; 31 (5) 899-904
• 4 Balsells M, García-Patterson A, Gich I, Corcoy R. Major congenital malformations in women with gestational diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012; 28 (3) 252-257
• 5 Metzger BE, Lowe LP, Dyer AR , et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358 (19) 1991-2002
• 6 Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMC Pregnancy Childbirth 2006; 6: 30
• 7 Feig DS, Hwee J, Shah BR, Booth GL, Bierman AS, Lipscombe LL. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996-2010. Diabetes Care 2014; 37 (6) 1590-1596
• 8 HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes 2009; 58 (2) 453-459
• 9 Stubbs SM, Doddridge MC, John PN, Steel JM, Wright AD. Haemoglobin A1 and congenital malformation. Diabet Med 1987; 4 (2) 156-159
• 10 Miller JL, de Veciana M, Turan S , et al. First-trimester detection of fetal anomalies in pregestational diabetes using nuchal translucency, ductus venosus Doppler, and maternal glycosylated hemoglobin. Am J Obstet Gynecol 2013; 208 (5) 385.e1-385.e8
• 11 Cefalu WT, Parker TB, Johnson CR. Validity of serum fructosamine as index of short-term glycemic control in diabetic outpatients. Diabetes Care 1988; 11 (8) 662-664
• 12 Kennedy DM, Johnson AB, Hill PG. A comparison of automated fructosamine and HbA1c methods for monitoring diabetes in pregnancy. Ann Clin Biochem 1998; 35 (Pt 2) 283-289
• 13 Lurie S. Age distribution of erythrocyte population in late pregnancy. Gynecol Obstet Invest 1990; 30 (3) 147-149
• 14 Committee on Practice Bulletins–Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. Obstet Gynecol 2013; 122 (2 Pt 1): 406-416
• 15 Tennant PW, Glinianaia SV, Bilous RW, Rankin J, Bell R. Pre-existing diabetes, maternal glycated haemoglobin, and the risks of fetal and infant death: a population-based study. Diabetologia 2014; 57 (2) 285-294
• 16 Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007; 30 (7) 1920-1925
• 17 Widness JA, Schwartz HC, Thompson D, Kahn CB, Oh W, Schwartz R. Haemoglobin Aic (glycohaemoglobin) in diabetic pregnancy: an indicator of glucose control and fetal size. Br J Obstet Gynaecol 1978; 85 (11) 812-817
• 18 Landon MB, Spong CY, Thom E , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361 (14) 1339-1348
• 19 de Veciana M, Major CA, Morgan MA , et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333 (19) 1237-1241
• 20 Langer O, Kozlowski S, Brustman L. Abnormal growth patterns in diabetes in pregnancy: a longitudinal study. Isr J Med Sci 1991; 27 (8–9) 516-523
• 21 The Diabetes Control Complications Trial Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174 (4) 1343-1353
• 22 Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 2005; 192 (4) 989-997
• 23 Murphy HR, Rayman G, Lewis K , et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008; 337: a1680
• 24 Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS ; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352 (24) 2477-2486
• 25 Lowe LP, Metzger BE, Dyer AR , et al; HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care 2012; 35 (3) 574-580
• 26 Reis ZS, Miranda AP, Lage EM, Bragança RD, Costa CR, Cabral AC. Echocardiographic findings of congenital cardiopathies among fetuses of diabetic pregnant women and their relationship with plasma fructosamine levels. J Matern Fetal Neonatal Med 2011; 24 (7) 943-947
• 27 Gandhi RA, Brown J, Simm A, Page RC, Idris I. HbA1c during pregnancy: its relationship to meal related glycaemia and neonatal birth weight in patients with diabetes. Eur J Obstet Gynecol Reprod Biol 2008; 138 (1) 45-48
• 28 Murphy HR, Steel SA, Roland JM , et al; East Anglia Study Group for Improving Pregnancy Outcomes in Women with Diabetes (EASIPOD). Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med 2011; 28 (9) 1060-1067
• 29 Katon J, Williams MA, Reiber G, Miller E. Antepartum A1C, maternal diabetes outcomes, and selected offspring outcomes: an epidemiological review. Paediatr Perinat Epidemiol 2011; 25 (3) 265-276